Close
Nordic 9Nordic 9

Pureos Bioventures (investor - Venture Capital)

Switzerland pureosbio.com
See something wrong or missing? Let us know
Offices:Zurich

BB Pureos Bioventures is a $170M venture fund from Switzerland, which invests venture capital in private innovative drug development companies, with an emphasis on the next generation of biological drugs.

Average round investment:52.29M USD
Average number per year:3.6
Distribution: 2025 (1)2024 (4)2023 (5)2022 (4)2020 (4)
Portfolio companies: Netherlands AdcytherixSweden AnaCardioNetherlands Citryll See the entire list
Mostly invests in: Switzerland Switzerland (6) Health services (16)
See the entire list

Showing 3 of 18 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Pureos Bioventures mostly invests with:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Pureos Bioventures

Name Criteria
United States MassMutual Ventures
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B, SAAS
  • Common investees countries: Germany, France, Sweden
  • Average number of deals per year: 4.2
  • Active last 12 months: Yes
Japan SBI Holdings
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B, SAAS
  • Common investees countries: Switzerland, Denmark, Germany
  • Average number of deals per year: 4.1
  • Active last 12 months: Yes
France Cap Horn
92%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B, SAAS
  • Common investees countries: Switzerland, Germany, France
  • Average number of deals per year: 3.9
  • Active last 12 months: Yes
Netherlands Inkef Capital
91%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B, SAAS
  • Common investees countries: Switzerland, Netherlands, Denmark, Germany
  • Average number of deals per year: 4.9
  • Active last 12 months: Yes
United Kingdom IP Group
91%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B, SAAS
  • Common investees countries: Germany, Sweden
  • Average number of deals per year: 5.2
  • Active last 12 months: Yes
United Kingdom Legal & General
91%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B, SAAS
  • Common investees countries: Sweden
  • Average number of deals per year: 3.2
  • Active last 12 months: Yes
United States Paladin Capital Group
91%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B, SAAS
  • Common investees countries: Switzerland, Germany, Sweden
  • Average number of deals per year: 2.9
  • Active last 12 months: Yes
Ireland Seroba Life Sciences
91%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B, SAAS
  • Common investees countries: Netherlands, Germany, France
  • Average number of deals per year: 2.5
  • Active last 12 months: Yes
Belgium Korys
91%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B, SAAS
  • Common investees countries: Netherlands, Germany, Sweden
  • Average number of deals per year: 2.3
  • Active last 12 months: Yes
Belgium Vives Fund
91%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Pharma
  • Similar business models: B2B, SAAS
  • Common investees countries: France
  • Average number of deals per year: 2.2
  • Active last 12 months: Yes
Top